Harnessing TIGIT Checkpoint Inhibitor Therapies as the Next Pillar of Frontline Cancer Treatments

Welcome to the TIGIT Therapies Digital Summit

The TIGIT checkpoint has gained much attention in recent years due to the number of roles it plays in several malignancies. TIGIT’s diverse function in multiple cell types has made it a lucrative immunotherapy candidate, with an increasing number of candidates being investigated in pre-clinical and clinical settings.

As evidence of TIGIT’s clinical potential builds, the TIGIT Therapies Digital Summit brings you a comprehensive insight, from the fundamental biology to early clinical development, and the next wave of ICI.

Hear from leaders in TIGIT development from Merck, Compugen, iTeos Therapeutics, Agenus and more!

World-Class Speaker Faculty

Dhan Chand

Scientific Director, Head of Drug Discovery

Agenus Inc.

Eran Ophir

Vice President Research & Discovery

Compugen Inc.

Jane Ann Healy

Executive Director Oncology Early Development

Merck

Yvonne McGrath

Vice President Research & Development

iTeos Therapeutics

Hassane Zarour

Professor of Medicine, Immunology & Dermatology

UPMC Hillman Cancer Center

Jane Grogan

CSO

Arsenal Bio

Sybil Williams

Director

Merck

Vijay Kuchroo

Director, Evergrande Center for Immunologic Diseases

Harvard Medical School and Brigham and Women’s Hospital

"Please join me at the meeting as we unravel the role TIGIT plays in promoting immune suppression in the tumor microenvironment and how we are leveraging these novel discoveries to build more effective TIGIT therapies for patients."

Dhan Chand, Scientific Director, Head of Drug Discovery, Agenus